In 2021, Parkinson’s research drove significant progress. Our Year in Review publication looks back on Parkinson’s breakthroughs and ahead to what’s coming in 2022 and beyond.
An important year for Parkinson’s research saw strides powered by our community — from discoveries in donor-funded lab studies to efforts expanding our understanding of the global impact of disease. These programs propel a robust and growing pipeline of new treatments closer to patient hands.
Our “2021 in Review and What's Next: Where the Power of Science Meets the Power of Community” publication reviews findings and plans in the following areas:
- Transforming the drug development landscape: What we’re tracking around alpha-synuclein, LRRK2, and other promising targets
- Understanding the biology of Parkinson’s: The latest on our landmark Progression Markers Initiative (PPMI) to predict and prevent Parkinson’s
- Creating momentum with our community: MJFF’s work around increasing inclusiveness in Parkinson’s research
